A combination of Btz and HDAC inhibitor, SAHA could effectively reactivate KSHV, thereby inducing PEL cell death and increasing survival in PEL-bearing mice, and strongly advocates using the proteasome/HDAC inhibitor combination therapy in PEL (Bhatt et al., 2013). The gene discussed is CASC3; the disease is primary effusion lymphoma.